0.05USD
3:59pm EST
$0.00 (+1.96%)
$0.05
$0.05
$0.06
$0.05
52,133
127,292
$0.60
$0.05
ANSV.PK
About
Overall
| Beta: | 2.23 |
| Market Cap (Mil.): | $2.06 |
| Shares Outstanding (Mil.): | 40.47 |
| Annual Dividend: | 0.00 |
| Yield (%): | NA |
Financials
| ANSV.PK | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 11.50 | 3.76 |
| EPS (TTM): | 57.05 | -- | -- |
| ROI: | -556.92 | 1.25 | 2.30 |
| ROE: | -612.59 | 2.09 | 2.82 |
UPDATE 1-Anesiva says to seek bankruptcy after deal fails
NEW YORK, Dec 31 (Reuters) - Anesiva Inc , a developer of pharmaceutical products for chronic pain, said on Thursday it will file for bankruptcy after it was unable to complete a proposed merger with Arcion Therapeutics Inc.
UPDATE 1-Anesiva gets OK to expand use of pain drug Zingo
Jan 9 (Reuters) - Anesiva Inc said U.S. health regulators approved its application to expand the use of Zingo, which is used treat the pain associated with blood draws, to include adults, sending its shares up 66 percent.
Anesiva's pain drug meets main goal; shares zoom
BANGALORE (Reuters) - Anesiva Inc's experimental pain drug Adlea met the main goal of a late-stage trial, raising hopes that the tiny biopharmaceutical company may find a partner to further develop the drug and prompting a six-fold jump in its market value.
Anesiva's pain drug meets main goal; shares zoom
BANGALORE (Reuters) - Anesiva Inc's experimental pain drug Adlea met the main goal of a late-stage trial, raising hopes that the tiny biopharmaceutical company may find a partner to further develop the drug and prompting a six-fold jump in its market value.
Anesiva shares sink on failed pain drug, restructuring
BANGALORE (Reuters) - Shares of Anesiva Inc
UPDATE 1-Anesiva pain drug fails late-stage trial, cuts jobs
main goal of a late-stage trial, and it also plans to withdraw
Anesiva files for $50 million debt, stock shelf
WASHINGTON, Nov 13 (Reuters) - Anesiva Inc filed with regulators on Tuesday to periodically sell up to $50 million in common and preferred stock, debt securities, warrants, and units.
Anesiva Q3 results
ANESIVA INC : * Third quarter per share loss $0.58 * Reuters Estimates third quarter per share view $-0.61 * Says updated guidance reduces full year loss by $5 million * Forecasts fiscal year net loss between $50 million and $55 million, before non-cash stock compensation * Reuters Estimates fiscal year 2007 per share view $-2.23
Competitors
| Price | Change | |
|---|---|---|
| Johnson & Johnson (JNJ.N) | $62.76 | +0.39 |
| Pfizer Inc. (PFE.N) | $17.88 | +0.04 |
| Merck & Co., Inc. (MRK.N) | $36.47 | -0.12 |
| GlaxoSmithKline plc (GSK.L) | £1,218.50 | -0.50 |
| Abbott Laboratories (ABT.N) | $53.35 | 0.00 |
| Amgen, Inc. (AMGN.OQ) | $57.21 | -0.25 |
| Eli Lilly & Co. (LLY.N) | $35.20 | +0.42 |
| Genzyme Corporation (GENZ.OQ) | $54.87 | +0.38 |
| Fresenius SE (FREG.DE) | €43.56 | -0.56 |
| Schwarz Pharma AG (SRZG.DE) | -- | -- |
Earnings vs 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
